Cervical Dysplasia – Pipeline Review, 2024

Cervical dysplasia is a precancerous condition which occurs due to abnormal growth of cells in and around the surface of the cervix. On the basis of severity, the cervical dysplasia is classified into mild, moderate, and severe. Human papillomavirus (HPV) infection is one of the prominent risk factor responsible for the occurrence of cervical dysplasia. HPV and cervical dysplasia can weaken the immune system, which turns patiently vulnerable to diseases such as HIV and AIDS. According to data published by Biomedical Research and Therapy, in 2012 an estimated 528,000 new cases in the U.S. were diagnosed with cervical cancer.

Certain preventive measures such as protective sexual intercourse, avoidance of smoking and monogamy can be helpful to avoid cervical dysplasia. Moreover, treatments such as concurrent chemoradiation with Cisplatin plus 5-fluorouracil, organ transplant, and cryotherapy can be adopted to cure cervical dysplasia. Combined with this, Carboplatin, Paclitaxel (Taxol), Topotecan, and Gemcitabine (Gemzar) can also be used to treat cervical dysplasia.

Academic and research institutes are focusing on studying and developing new treatment options for cervical dysplasia. For instance; Nelfinavir, which is being studied by The University of Texas Health Science Center, Houston, is currently in phase-2 clinical trials to check its efficacy in the treatment of cervical dysplasia.

To know how our report can help streamline your business, Speak to Analyst

At present, around 70% of the pipeline candidates for Cervical Dysplasia are in the phase-2 and phase-3 stages combined. Majority of the studies have been sponsored by research institutes and academic research centers.

Report Description

The report on ‘Cervical Dysplasia – Pipeline Review, 2024’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for cervical dysplasia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for cervical dysplasia.

The report on ‘Cervical Dysplasia – Pipeline Review, 2024’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target


• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration


• Overview of dormant and discontinued pipeline products


• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products


• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.


• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for cervical dysplasia


• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players


• Identify the focus of leading players in relation to R&D for cervical dysplasia


• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business


• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary